Carnegie Asset Management
VC Fund
Copenhagen, Denmark
Carnegie Asset Management is a focused and independent asset manager. Their objective is to deliver consistent, long term asset growth for their clients. The combination of a unique investment philosophy based on careful stock-picking and long-term global trends coupled with a stable team of experienced portfolio managers, has over the past 20years resulted in world-class investment results.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Carnegie Asset Management invests in
Stages Carnegie Asset Management invests in
Countries Carnegie Asset Management invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Pharmaceutical 2 (50%)
- Genetics 1 (25%)
- Health Care 1 (25%)
- Life Science 1 (25%)
Stage
- Series C 2 (50%)
- Series B 1 (25%)
- Funding Round 1 (25%)
Country
- Canada 1 (25%)
- Switzerland 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. | $16.5M / Series C / Oct 05, 2006 | ||
| Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population. | $12M / Mar 29, 2006 | ||
| Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy. | $17.6M / Series B / Dec 20, 2005 | ||
| Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based inSanta Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc. | $42.8M / Series C / Mar 04, 2002 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Carnegie Asset Management invest in?
Carnegie Asset Management invests primarily in Biotechnology, Pharmaceutical and Genetics startups, most often at Series C and Series B stage. Most of the 4 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Carnegie Asset Management last invest?
The most recent investment recorded for Carnegie Asset Management closed in Oct 2006. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
